Logo

Anti-alpha-enolase antibodies in Behçet's disease: a marker of mucocutaneous and articular disease activity?

1, 2, 3, 4, 5

  1. Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Brazil. leandro.prado@hc.fm.usp.br
  2. Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Brazil.
  3. Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Brazil.
  4. Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Brazil.
  5. Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Brazil.

CER10739 Submission on line
Full Papers

Rheumatology Article

 

Abstract

OBJECTIVES:
To assess IgM anti-alpha-enolase antibodies (AAEA) in systemic Behçet’s disease (BD) and its possible association with clinical manifestations and disease activity.
METHODS:
Ninety-seven consecutively selected BD patients were compared to 36 enteropathic spondyloarthritis (ESpA) [24 Crohn’s disease (CD) and 12 ulcerative colitis (UC)] patients and 87 healthy controls. IgM AAEA was detected by immunoblotting. Disease activity was assessed by standardised indexes, Brazilian BD Current Activity Form (BR-BDCAF) for BD and Harvey-Bradshaw Index (HBI) for CD and UC patients. A second evaluation was performed in BD patients (n=56), regarding IgM AAEA presence, disease activity scores and C-reactive protein (CRP).
RESULTS:
Higher IgM AAEA prevalence was found in 97 BD (17.7%) compared to ESpA (2.8%) and healthy controls (2.3%), p<0.001. IgM AAEA frequency was higher in active BD compared to inactive BD (30.2% vs. 7.4%, p=0.006), a finding confirmed in the second cross-sectional evaluation of 56 of these BD patients (45.5% vs. 13.3%, p=0.02). Mean BR-BDCAF scores were higher in IgM AAEA positive group on both evaluations (9.1 ± 5.4 vs. 4.9 ± 4.9, p=0.002; 5.0 ± 4.9 vs. 2.2 ± 2.9, p=0.01, respectively). BD patients with mucocutaneous and articular symptoms presented higher IgM AAEA positivity in the first and second evaluations (64.7% vs. 27.5%, p=0.005; 36.4% vs. 7.1%, p=0.039 respectively).
CONCLUSIONS:
Our data support the notion that alpha-enolase is a target antigen in BD, particularly associated with disease activity, mucocutaneous and articular involvement. In addition, IgM AAEA may distinguish BD from ESpA, especially in patients with high disease activity.

PMID: 29465373 [PubMed]

Received: 07/08/2017 - Accepted : 11/12/2017 - In Press: 07/02/2018